hydron;N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;chloride (BioDeep_00001080263)

   


代谢物信息卡片


hydron;N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;chloride

化学式: C17H26ClN3O2S (371.1434166)
中文名称:
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: [H+].CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C.[Cl-]
InChI: 1H

描述信息

同义名列表

1 个代谢物同义名

hydron;N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;chloride



数据库引用编号

1 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Kentaro Tokuoka, Risa Takayanagi, Yuji Suzuki, Masayuki Watanabe, Yasuhisa Kitagawa, Yasuhiko Yamada. Theory-based analysis of clinical efficacy of triptans using receptor occupancy. The journal of headache and pain. 2014 Dec; 15(?):85. doi: 10.1186/1129-2377-15-85. [PMID: 25488888]
  • Venkata Suresh Ponnuru, B R Challa, Ramarao Nadendla. Quantitative analysis of eletriptan in human plasma by HPLC-MS/MS and its application to pharmacokinetic study. Analytical and bioanalytical chemistry. 2011 Nov; 401(8):2539-48. doi: 10.1007/s00216-011-5341-4. [PMID: 21892641]
  • Manish Yadav, Chirag Patel, Mahendra Patel, Tulsidas Mishra, Girin A Baxi, Puran Singhal, Pranav S Shrivastav. Development and validation of a sensitive and rapid method to determine naratriptan in human plasma by LC-ESI-MS-MS: application to a bioequivalence study. Journal of chromatographic science. 2011 Feb; 49(2):101-7. doi: 10.1093/chrsci/49.2.101. [PMID: 21223633]
  • Necla Calışkan, Eda Sögüt, Cafer Saka, Yavuz Yardım, Zuhre Sentürk. The natural diatomite from caldiran-van (Turkey): electroanalytical application to antimigraine compound naratriptan at modified carbon paste electrode. Combinatorial chemistry & high throughput screening. 2010 Sep; 13(8):703-11. doi: 10.2174/138620710791920356. [PMID: 20426734]
  • Peer Tfelt-Hansen. Parenteral vs. oral sumatriptan and naratriptan: plasma levels and efficacy in migraine. a comment. The journal of headache and pain. 2007 Oct; 8(5):273-6. doi: 10.1007/s10194-007-0411-x. [PMID: 17955173]
  • David C Evans, Desmond O'Connor, Brian G Lake, Raymond Evers, Christopher Allen, Richard Hargreaves. Eletriptan metabolism by human hepatic CYP450 enzymes and transport by human P-glycoprotein. Drug metabolism and disposition: the biological fate of chemicals. 2003 Jul; 31(7):861-9. doi: 10.1124/dmd.31.7.861. [PMID: 12814962]
  • K Zimmermann, W P Reeh, B Averbeck. S+ -flurbiprofen but not 5-HT1 agonists suppress basal and stimulated CGRP and PGE2 release from isolated rat dura mater. Pain. 2003 Jun; 103(3):313-320. doi: 10.1016/s0304-3959(02)00459-1. [PMID: 12791437]
  • N Einer-Jensen, L Larsen, S Deprez, E Starns, S Schwartz. Intranasal absorption of sumatriptan and naratriptan: no evidence of local transfer from the nasal cavities to the brain arterial blood in male rats. Biopharmaceutics & drug disposition. 2001 Jul; 22(5):213-9. doi: 10.1002/bdd.281. [PMID: 11745923]
  • M L Christensen, S K Eades, E Fuseau, R D Kempsford, S J Phelps, L J Hak. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. Journal of clinical pharmacology. 2001 Feb; 41(2):170-5. doi: 10.1177/00912700122009980. [PMID: 11210397]
  • D Deleu, Y Hanssens. Current and emerging second-generation triptans in acute migraine therapy: a comparative review. Journal of clinical pharmacology. 2000 Jul; 40(7):687-700. doi: 10.1177/00912700022009431. [PMID: 10883409]
  • K Vishwanathan, M G Bartlett, J T Stewart. Determination of antimigraine compounds rizatriptan, zolmitriptan, naratriptan and sumatriptan in human serum by liquid chromatography/electrospray tandem mass spectrometry. Rapid communications in mass spectrometry : RCM. 2000; 14(3):168-72. doi: 10.1002/(sici)1097-0231(20000215)14:3<168::aid-rcm861>3.0.co;2-9. [PMID: 10637423]
  • A MaassenVanDenBrink, M Reekers, W A Bax, M D Ferrari, P R Saxena. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation. 1998 Jul; 98(1):25-30. doi: 10.1161/01.cir.98.1.25. [PMID: 9665056]
  • H E Connor, W Feniuk, D T Beattie, P C North, A W Oxford, D A Saynor, P P Humphrey. Naratriptan: biological profile in animal models relevant to migraine. Cephalalgia : an international journal of headache. 1997 May; 17(3):145-52. doi: 10.1046/j.1468-2982.1997.1703145.x. [PMID: 9170336]
  • B D Duléry, M A Petty, J Schoun, M David, N D Huebert. A method using a liquid chromatographic-electrospray-mass spectrometric assay for the determination of antimigraine compounds: preliminary pharmacokinetics of MDL 74,721, sumatriptan and naratriptan, in rabbit. Journal of pharmaceutical and biomedical analysis. 1997 Apr; 15(7):1009-20. doi: 10.1016/s0731-7085(96)01955-3. [PMID: 9160269]